Abstracts tagged "Bone density and rheumatoid arthritis (RA)"

Abstract Number: 485 • 2018 ACR/ARHP Annual Meeting
Bone Loss in Different Sites over Time in Patients with Rheumatoid Arthritis
Rachel Tribbick¹, Marco Massarotti², Jemma G Kerns³, Frank Dondelinger¹ and Marwan Bukhari⁴, ¹CHICAS, Lancaster University, Lancaster, United Kingdom, ²Rheumatology, Royal Lancaster Infirmary, University Hospital of Morecambe Bay NHS Foundation Trust, Lancaster, United Kingdom, ³Medical School, Lancaster University, Lancaster, United Kingdom, ⁴Royal Lancaster Infirmary, Lancaster, United Kingdom
Background/Purpose: Rheumatoid arthritis (RA) is described as an independent risk factor for osteoporosis and is included in models, including the FRAX™ tool which uses bone…
Abstract Number: 1313 • 2015 ACR/ARHP Annual Meeting
Tumour Necrosis Factor Inhibitor Treatment Normalises Hand Bone Loss in a Minority of Rheumatoid Arthritis Patients Treated in Clinical Practice. Results from the Copenhagen Osteoarthritis Study and the Danbio Registry
Lykke Midtbøll Ørnbjerg¹, Mikkel Østergaard¹, Trine David Jensen², Pernille Bach Mortensen², Lars Hyldstrup², Pernille Boyesen³, Anja Thormann¹, Ulrik Tarp¹, Wolfgang Bøhme¹, Hanne Lindegaard¹, Uta Engling Poulsen¹, Annette Hansen¹, Annette Schlemmer¹, Niels Graudal¹, Anne Rødgaard Andersen¹, Jakob Espesen¹, Gina Kollerup¹, Bente Glintborg¹, Ole Rintek Madsen¹, Dorte Vendelbo Jensen¹ and Merete Lund Hetland¹, ¹DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ²Dept. of Endocrinology, Hvidovre Hospital, Copenhagen, Denmark, ³Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Rheumatoid arthritis (RA) is characterised by progressive joint destruction and loss of periarticular bone mass. Thus hand bone loss (HBL) has been proposed as…
Abstract Number: 2110 • 2012 ACR/ARHP Annual Meeting
Prospective Assessement of Bone Texture Parameters At the Hand in Rheumatoid Arthritis
Laetitia Sparsa¹, Sami Kolta¹, Karine Briot¹, Simon Paternotte¹, Rashra Masri², Damien Loeuille², Piet P. Geusens³ and Christian Roux¹, ¹Rheumatology B, Paris Descartes University, Cochin hospital, Paris, France, ²Rheumatology, CHU Brabois, Vandoeuvre les Nancy, France, ³UH & MUMC & ReumaClinic, Genk, Belgium
Background/Purpose: Bone and cartilage loss and destruction is associated with rheumatoid arthritis (RA) and inflammation. There is a need for tools for prediction of potential…
Abstract Number: 361 • 2012 ACR/ARHP Annual Meeting
Impact of Tumour Necrosis Factor Inhibitor Treatment On Hand Bone Loss in Rheumatoid Arthritis Patients Treated in Clinical Practice. Results From the Nationwide Danish Danbio Registry
Lykke Midtbøll Ørnbjerg¹, Mikkel Østergaard², Pernille Bøyesen³, Trine David Jensen⁴, Anja Thormann², Ulrik Tarp², Wolfgang Bøhme², Ditte Dencker², Hanne M. Lindegaard⁵, Uta Engling Poulsen², Annette Hansen⁶, Vibeke Stevenius Ringsdal², Annette Schlemmer⁷, Niels Graudal², Anne Rødgaard Andersen², Jakob Espesen², Gina Kollerup², Torben Grube Christensen², Randi Pelck², Bente Glintborg², Ole Rintek Madsen², Dorte Vendelbo Jensen², Ole Majgaard² and Merete L. Hetland⁸, ¹Copenhagen Center for Arthritis Reasearch, Center for Rheumatology and Spine diseases, Glostrup Hospital, Copenhagen, Denmark, ²DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, ³Rheumatology, Diakonhjemmet Hospital, Olso, Norway, ⁴Dept. of Endocrinology, Hvidovre Hospital, Copenhagen, Denmark, ⁵Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁶Department of Rheumatology, Gentofte University Hospital, Copenhagen, Denmark, ⁷Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ⁸Copenhagen University Hospital Glostrup, Copenhagen, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is characterised by progressive joint destruction and periarticular bone loss. In RA patients with insufficient response to Disease-Modifying Anti-rheumatic drugs (DMARDs)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].